Abstract | OBJECTIVE: METHODS: RESULTS: Sera of 34/109 SLE patients (31%) reacted specifically with the NR2A peptide compared with only 4/65 myasthenia gravis patients (6.1%, p<0.001), 1/19 APS I patients (5.3%, p<0.02), and 3/65 healthy controls (4.6%, p<0.001). No correlation was found between the presence of NR2A and dsDNA or anti- cardiolipin specific autoantibodies. In addition, no significant correlation was observed between the presence of NR2A specific antibodies and the SLEDAI score or any lupus related clinical manifestations. CONCLUSIONS:
|
Authors | E S Husebye, Z M Sthoeger, M Dayan, H Zinger, D Elbirt, M Levite, E Mozes |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 64
Issue 8
Pg. 1210-3
(Aug 2005)
ISSN: 0003-4967 [Print] England |
PMID | 15708887
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Antinuclear
- Autoantibodies
- NR2A NMDA receptor
- Receptors, N-Methyl-D-Aspartate
- DNA
|
Topics |
- Adult
- Antibodies, Antinuclear
(blood)
- Autoantibodies
(blood)
- DNA
(immunology)
- Enzyme-Linked Immunosorbent Assay
(methods)
- Female
- Humans
- Lupus Erythematosus, Systemic
(immunology)
- Male
- Middle Aged
- Myasthenia Gravis
(immunology)
- Polyendocrinopathies, Autoimmune
(immunology)
- Receptors, N-Methyl-D-Aspartate
(immunology)
- Severity of Illness Index
|